Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Web Exclusives
Tornado Sweeps Through Pfizer’s Storage and Manufacturing Facility
FDA Approvals, News & Updates
Web Exclusives
— August 7, 2023
On July 19, 2023, an EF3 tornado touched down in Rocky Mount, NC, badly damaging a Pfizer drug manufacturing facility that is responsible for producing nearly 25% of Pfizer’s sterile injectable medicines used in US hospitals.
Read Article
Results from Phase 3 Trial Show Similar Efficacy and Safety Outcomes with CT-P16 versus Bevacizumab in Patients with NSCLC
Biosimilars
Web Exclusives
— January 31, 2023
One-year follow-up data from a phase 3 study found similar duration of response, time to progression (TTP), and survival rates with the biosimilar candidate CT-P16 compared with its reference drug, bevacizumab (Avastin), in the first-line treatment of patients with metastatic or recurrent nonsquamous non–small-cell lung cancer (NSCLC).
Read Article
A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients
JCP Special Report
Web Exclusives
— December 5, 2022
In an interview, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
Read Article
Multicenter International Prospective Trial on Gallium-68 PSMA PET/CT Imaging Confirms Accuracy in Detecting Prostate Cancer Recurrence
Prostate Cancer Diagnostics
Web Exclusives
— October 19, 2021
Gallium-68 PSMA PET/CT imaging in patients with early relapsed prostate cancer confirms the reliability of this imaging modality in local and metastatic lesion detection.
Read Article
Diagnostic Capability in Relapsed Prostate Cancer Improved with ¹⁸F-DCFPyL PET/CT Imaging
Prostate Cancer Diagnostics
Web Exclusives
— October 19, 2021
Recently released analysis of
18
F-DCFPyL PET/CT accuracy demonstrated improved diagnostic capability in men with biochemical recurrence of prostate cancer.
Read Article
NaF PET Imaging Demonstrates Increased Sensitivity for New Lesion Detection for Patients with Metastatic Prostate Cancer
Prostate Cancer Diagnostics
Web Exclusives
— October 19, 2021
NaF PET imaging study demonstrates an increased sensitivity over Tc99m-MDP bone scans for new lesion detection in patients with stable metastatic prostate cancer.
Read Article
Recent Study Results Finds ¹⁸F-Fluciclovine PET/CT Alters Recurrent Prostate Cancer Management
Prostate Cancer Diagnostics
Web Exclusives
— October 19, 2021
Salvage radiotherapy decisions for patients with recurrent prostate cancer after prostatectomy change after
18
F-fluciclovine PET/CT reveals higher positive findings than conventional imaging.
Read Article
Whole-Body MRI Found Superior to Bone Scan for Prognosis in Patients with Metastatic Prostate Cancer
Prostate Cancer Diagnostics
Web Exclusives
— October 19, 2021
Recently released study results indicate whole-body MRI is superior to bone scan for prognosis in patients with metastatic hormone-naïve prostate cancer.
Read Article
Researchers Released Data from a Clinical Trial Investigating Fluorine 18 Fluciclovine PET/CT Use to Identify Targets for Site-Directed Therapy
Prostate Cancer Diagnostics
Web Exclusives
— September 29, 2021
Investigators released participant group data from a clinical trial looking at the use of fluorine 18 fluciclovine PET/CT in men with prostate cancer and biochemical recurrence to identify potential targets for therapy.
Read Article
EMPIRE-1 Phase 2/3 Trial Results Indicate Fluorine 18 Fluciclovine PET/CT Utilization May Confer Event-Free Survival Advantage
Prostate Cancer Diagnostics
Web Exclusives
— September 29, 2021
The recent release of EMPIRE-1 phase 2/3 trial results indicates the use of fluorine 18 fluciclovine PET/CT to guide salvage postprostatectomy radiotherapy increases event-free survival from biochemical recurrence or persistence.
Read Article
Page 1 of 11
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma